Penetrance of a rare familial mutation predisposing to papillary thyroid cancer

被引:0
作者
Donika Saporito
Pamela Brock
Heather Hampel
Jennifer Sipos
Soledad Fernandez
Sandya Liyanarachchi
Albert de la Chapelle
Rebecca Nagy
机构
[1] MD Anderson Cancer Center,Department of Clinical Cancer Genetics
[2] The Ohio State University Wexner Medical Center,Division of Human Genetics
[3] The Ohio State University,Division of Human Genetics, Department of Internal Medicine and the Comprehensive Cancer Center
[4] The Ohio State University Wexner Medical Center,Division of Endocrinology, Diabetes and Metabolism
[5] The Ohio State University Wexner Medical Center,Department of Biomedical Informatics
[6] The Ohio State University,Department of Cancer Biology and Genetics and the Comprehensive Cancer Center
[7] Guardant Health,Senior Medical Science Liaison
来源
Familial Cancer | 2018年 / 17卷
关键词
Familial non-medullary thyroid cancer; Papillary thyroid cancer; Anaplastic thyroid cancer; Penetrance; Benign thyroid disease; Risk;
D O I
暂无
中图分类号
学科分类号
摘要
Familial non-medullary thyroid cancer (FNMTC) is clinically defined as two or more first-degree relatives with NMTC and appears to follow an autosomal dominant inheritance pattern. Approximately 5–7% of NMTC is hereditary and affects multiple generations with a young age of onset. The primary aim of this study was to determine the age-specific penetrance of NMTC in individuals from a large family with FNMTC with a previously identified private mutation at 4q32, with a secondary aim to determine the penetrance for benign thyroid disease in this family. We present a large family with NMTC in which we had previously described a culpable mutation. Participants provided their personal medical history and family history. The germline 4q32 A > C mutation was detected in 34 of 68 tested individuals. Age-specific penetrance of thyroid cancer and benign thyroid disease was determined using the inverted Kaplan–Meier method of segregation analysis. Individuals who tested positive for the 4q32 mutation have a 68.9% (95% CI 46.5–88.7) risk of developing thyroid cancer by age 70 and a 65.3% (95% CI 46.0–83.8) risk of developing benign thyroid disease by age 70. The 4q32 A > C mutation significantly increases the risk to develop thyroid cancer but not benign thyroid disease in members of this family. The female:male sex ratio of 1.33 that we observed in affected mutation carriers differs greatly from the ratio of approximately 3:1 observed in PTC, supporting a central role of the mutation. Early thyroid surveillance with annual ultrasound is recommended to individuals testing positive for this private familial mutation.
引用
收藏
页码:431 / 434
页数:3
相关论文
共 22 条
  • [1] Haugen BR(2016)2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer Thyroid 26 1-133
  • [2] Alexander EK(2007)An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up World J Surg 31 924-933
  • [3] Bible KC(2002)Environmental and heritable causes of cancer among 9.6 million individuals in the swedish family-cancer database Int J Cancer 99 260-266
  • [4] Doherty GM(1994)Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands J Natl Cancer Inst 86 1600-1608
  • [5] Mandel SJ(2013)Ultra-rare mutation in long-range enhancer predisposes to thyroid carcinoma with high penetrance PLoS ONE 8 e61920-1104
  • [6] Nikiforov YE(2009)Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases Surgery 146 1099-undefined
  • [7] Sippel RS(undefined)undefined undefined undefined undefined-undefined
  • [8] Caron NR(undefined)undefined undefined undefined undefined-undefined
  • [9] Clark OH(undefined)undefined undefined undefined undefined-undefined
  • [10] Czene K(undefined)undefined undefined undefined undefined-undefined